We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01751451
First Posted: December 18, 2012
Last Update Posted: April 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Janssen Scientific Affairs, LLC
OHSU Knight Cancer Institute
Rutgers Cancer Institute of New Jersey
NorthShore University HealthSystem
Duke University
Feinberg School of Medicine, Northwestern University
Sidney Kimmel Comprehensive Cancer Center
University of North Carolina
Wayne State University
Perlmutter New York University Cancer Center
Weill Medical College of Cornell University
Ferring Pharmaceuticals
GU Research Network, LLC
University of California, Los Angeles
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2018
  Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)